Ascendis Pharma A/S
NASDAQ Global SelectTotal Valuation
Ascendis Pharma A/S carries a market capitalization of 13.39B, placing it among publicly traded companies globally. Its enterprise value stands at 12.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13.39B |
| Enterprise Value | 12.40B |
Share Statistics
Ascendis Pharma A/S currently has 61.78M shares outstanding.
| Shares Outstanding | 61.78M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Ascendis Pharma A/S trades at a trailing price-to-earnings ratio of 24.34. The price-to-sales ratio is 13.94, and the price-to-book ratio stands at 1,440.64.
| PE Ratio | 24.34 |
| PS Ratio | 13.94 |
| PB Ratio | 1,440.64 |
| P/TBV Ratio | 24.93 |
| P/FCF Ratio | 181.40 |
| P/OCF Ratio | 199.58 |
Enterprise Valuation
| EV / Sales | 14.32 |
| EV / EBITDA | 1,858.25 |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Ascendis Pharma A/S maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 183.75, indicating elevated leverage, while an interest coverage ratio of 0.05 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.00 |
| Quick Ratio | 0.68 |
| Debt / Equity | 183.75 |
| Debt / EBITDA | 134.41 |
| Interest Coverage | 0.05 |
Financial Efficiency
| Return on Equity (ROE) | -9,704.51 |
| Return on Assets (ROA) | 32.36 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.31 |
Taxes
| Income Tax | -663.19M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Ascendis Pharma A/S's stock has gained approximately 24.30619% over the past 52 weeks. The 50-day moving average sits at 232.80, while the 200-day moving average is 216.38.
| Beta (5Y) | N/A |
| 52-Week Price Change | 24.30619% |
| 50-Day Moving Average | 232.80 |
| 200-Day Moving Average | 216.38 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Ascendis Pharma A/S generated 865.78M in revenue and converted that into 495.93M in net income, yielding earnings per share of 7.93. EBITDA reached 6.67M, while operating income came in at -10.70M.
| Revenue | 865.78M |
| Gross Profit | 770.87M |
| Operating Income | -10.70M |
| Pretax Income | -167.26M |
| Net Income | 495.93M |
| EBITDA | 6.67M |
| EBIT | -10.70M |
| Earnings Per Share (EPS) | 7.93 |
Balance Sheet
Ascendis Pharma A/S holds 572.82M in cash and equivalents against 896.66M in total debt, resulting in a net debt position of 323.84M. Total book value stands at 8.38M, with working capital of -4.42M providing operational flexibility.
| Cash & Cash Equivalents | 572.82M |
| Total Debt | 896.66M |
| Net Debt | 323.84M |
| Equity (Book Value) | 8.38M |
| Book Value Per Share | 0.14 |
| Working Capital | -4.42M |
Cash Flow
Ascendis Pharma A/S produced 60.49M in operating cash flow over the past twelve months. After subtracting -7.78M in capital expenditures, free cash flow totaled 52.71M - equivalent to 0.86 per share.
| Operating Cash Flow | 60.49M |
| Capital Expenditures | -7.78M |
| Free Cash Flow | 52.71M |
| FCF Per Share | 0.86 |
Margins
Ascendis Pharma A/S operates with a gross margin of 89.04, reflecting its pricing power and cost economics. The operating margin of -1.24 and net profit margin of 57.28 provide insight into operational efficiency.
| Gross Margin | 89.04 |
| Operating Margin | -1.24 |
| Pretax Margin | -19.32 |
| Profit Margin | 57.28 |
| EBITDA Margin | 0.77 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.15 |
| FCF Yield | 0.55 |
Scores
Ascendis Pharma A/S posts an Altman Z-Score of 5.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.19 |